Clinical trial
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as…
NCT00077350 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077350 |
|---|---|
| Title | A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of Triapine® (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Non-small Cell Lung Cancer |
| Intervention type | Drug, Other |
| Interventions | triapine, gemcitabine hydrochloride, laboratory biomarker analysis |
| Enrollment | 48 |
| Start date | Jul 1, 2004 |
| Primary completion | Apr 1, 2005 |
| First posted | Feb 12, 2004 |
| Last update posted | Feb 27, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: